A5036680223- Helicobacter pylori-related gastroenterology studies
- Gastrointestinal Bleeding Diagnosis and Treatment
- Gastroesophageal reflux and treatments
- Intramuscular injections and effects
- Colorectal Cancer Screening and Detection
- Clinical practice guidelines implementation
- Genetic factors in colorectal cancer
- Gastrointestinal motility and disorders
- Healthcare Policy and Management
- Heparin-Induced Thrombocytopenia and Thrombosis
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Toxin Mechanisms and Immunotoxins
- Drug-Induced Adverse Reactions
- Antibiotics Pharmacokinetics and Efficacy
- Peripheral Neuropathies and Disorders
GlaxoSmithKline (Canada)
2023-2025
GlaxoSmithKline (United States)
2023
AstraZeneca (Canada)
2009-2010
ClinicalTrials.gov identifier, NCT05280717.
BACKGROUND/OBJECTIVE: Guidelines for the management of patients with nonvariceal upper gastrointestinal bleeding (NVUGIB) are inconsistently applied by health care providers, potentially resulting in suboptimal and patient outcomes. A needs assessment was performed to assess providers’ barriers implementation these guidelines Canada. METHODS: Semistructured telephone interviews were conducted trained research personnel 22 selectively sampled professionals actively treating managing NVUGIB...
OBJECTIVE: To determine whether strategies to counsel and empower patients with heartburn-predominant dyspepsia could improve health-related quality of life. METHODS: Using a cluster randomized, parallel group, multicentre design, nine centres were assigned provide either basic or comprehensive counselling (age range 18 50 years) presenting upper gastrointestinal symptoms, who would be considered for drug therapy without further investigation. Patients treated four weeks esomeprazole 40 mg...
Sotrovimab 500 mg administered by a single intravenous (IV) infusion has been granted special approval for emergency use in Japan treatment of SARS-CoV-2 infection adults and children aged ≥ 12 years weighing 40 kg. This Phase 1, single-dose study investigated the pharmacokinetics, safety, tolerability IV or intramuscular (IM) sotrovimab doses versus placebo healthy Japanese Caucasian volunteers. was two-part, randomized, placebo-controlled, single-blind study. In Part participants received...
Abstract Background Sotrovimab is a dual-action Fc-engineered human monoclonal antibody (mAb), developed for early treatment of mild-to-moderate COVID-19. We evaluated the safety and tolerability sotrovimab 500 mg administered intramuscularly (IM) at dorsogluteal (DG), anterolateral (AL) thigh deltoid injection sites. Methods This Phase 1 open-label, parallel group, randomized, healthy volunteer study comprised three parts. Part A investigated relative bioavailability, 2 concentrations IM...
Purpose: Nonvariceal upper gastrointestinal bleeding (NVUGIB) causes substantial morbidity and mortality. Guidelines for the management of patients with NVUGIB exist, but are inconsistently applied by healthcare providers, resulting potentially in sub-optimal care patient outcomes. A needs assessment was carried out to assess providers’ barriers implementation these guidelines Canada. Methods: Semi-structured key informant interviews were conducted telephone a sample 22 selectively sampled...
Purpose: Inappropriate utilization of proton pump inhibitors (PPI) and H2-receptor antagonists (H2RA) in inpatients is prevalent, but not well defined due to a lack standardized grading system appropriateness. We undertook national audit better characterize this situation. Methods: For in-patients receiving PPI or H2RA, demographic, clinical, laboratory, endoscopic, pharmacological data were collected. Drug regimens reviewed by experts using adjudication rules. Regimens included intravenous...